MD Anderson and Xencor Enter Strategic Collaboration to Develop Novel T Cell-Engaging Bispecific Antibodies for Potential Treatment of Patients With Cancer
January 07, 2021
January 07, 2021
HOUSTON, Texas, Jan. 7 (TNSRes) -- The University of Texas's MD Anderson Cancer Center issued the following news release on Jan. 6:
The University of Texas MD Anderson Cancer Center and Xencor, Inc. today announced a strategic research collaboration and commercialization agreement to develop novel CD3 bispecific antibody therapeutics for the potential treatment of patients with cancer.
This collaboration joins Xencor's innovative XmAb(R) technology and protein engineeri . . .
The University of Texas MD Anderson Cancer Center and Xencor, Inc. today announced a strategic research collaboration and commercialization agreement to develop novel CD3 bispecific antibody therapeutics for the potential treatment of patients with cancer.
This collaboration joins Xencor's innovative XmAb(R) technology and protein engineeri . . .